Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership

▤ Summary

Pluristyx announced a Notice of Allowance from the Japanese Patent Office for synthetic mRNA technology that supports iPSC reprogramming. The company says the patent strengthens its intellectual property and validates its approach to faster, safer, and more scalable cell line generation. Pluristyx plans to use the protected technology to expand partnerships and give therapeutic developers access to clinical-grade iPSC lines and related services. The update matters for regenerative medicine teams that need compliant reprogramming, manufacturing scalability, and better cell therapy workflows.

▦ Linked Companies